Clinical equivalence of intranasal and oral 17β-estradiol for postmenopausal symptoms
- 1 March 2000
- journal article
- clinical trial
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 182 (3) , 545-552
- https://doi.org/10.1067/mob.2000.104843
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Efficacy and acceptability of intranasal 17 β-oestradiol for menopausal symptoms: randomised dose-response studyThe Lancet, 1999
- Risk of venous thromboembolism in users of hormone replacement therapyThe Lancet, 1996
- Postmenopausal Estrogen and Progestin Use and the Risk of Cardiovascular DiseaseNew England Journal of Medicine, 1996
- Pharmacokinetic and Pharmacologic Variation Between Different Estrogen ProductsThe Journal of Clinical Pharmacology, 1995
- Acceptability and skin reactions to transdermal estrogen replacement therapy in relation to climateMaturitas, 1994
- Hormonal Treatment of Postmenopausal WomenNew England Journal of Medicine, 1994
- A randomized comparison of nonoral estradiol delivery in postmenopausal womenAmerican Journal of Obstetrics and Gynecology, 1988
- Biological Effects of Estradiol-17β in Postmenopausal Women: Oral Versus percutaneous AdministrationJournal of Clinical Endocrinology & Metabolism, 1986
- LONG-TERM PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS BY ŒSTROGENThe Lancet, 1976
- COMPARATIVE CLINICAL EVALUATION OF ESTROGENIC PREPARATIONS BY THE MENOPAUSAL AND AMENORRHEAL INDICES*†Journal of Clinical Endocrinology & Metabolism, 1953